Mary Newman - Boundless Bio, Senior Vice President - Regulatory Affairs

President

Ms. Mary Newman is Senior Vice President Regulatory Affairs of the AUDENTES THERAPEUTICS, INC. Prior to joining Audentes, Ms. Newman served as the Senior Vice President, Regulatory Affairs and Quality Assurance at SARcode Bioscience Inc., which was acquired by Shire Ltd. She previously held various management positions, with increasing responsibility in Regulatory Affairs at BioMarin Pharmaceutical, Inc., Berlex Inc., and Sequus Pharmaceuticals, Inc. . While at BioMarin, Ms. Newman oversaw the development and approval of Kuvan for the treatment of phenylketonuria, Naglazyme for mucopolysaccharidosis VI, and supported the final approval of Aldurazyme for MPS I. She has also held various research and development leadership roles in oncology, neurology, and antifungal therapeutic areas since 2014.
Age 58
Tenure 10 years
Phone415 818-1001
Webwww.audentestx.com
Newman holds a B.S. in Physiology from Oregon State University.

Mary Newman Latest Insider Activity

Tracking and analyzing the buying and selling activities of Mary Newman against Boundless Bio, stock is an integral part of due diligence when investing in Boundless Bio,. Mary Newman insider activity provides valuable insight into whether Boundless Bio, is net buyers or sellers over its current business cycle. Note, Boundless Bio, insiders must abide by specific rules, including filing SEC forms every time they buy or sell Boundless Bio,'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Boundless Bio, Management Efficiency

The company has return on total asset (ROA) of (28.42) % which means that it has lost $28.42 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (50.57) %, meaning that it created substantial loss on money invested by shareholders. Boundless Bio,'s management efficiency ratios could be used to measure how well Boundless Bio, manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 29.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Boundless Bio, Common has a current ratio of 12.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Boundless Bio, until it has trouble settling it off, either with new capital or with free cash flow. So, Boundless Bio,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Boundless Bio, Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Boundless to invest in growth at high rates of return. When we think about Boundless Bio,'s use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Scott BowmanDave Busters Entertainment
51
Scott FelensteinNational CineMedia
55
Michael PlunkettDave Busters Entertainment
66
Scott PalmerSapiens International
N/A
Sarah HiltyNational CineMedia
47
Liana GelikasSapiens International
N/A
Lawrence SnappNational CineMedia
78
Joe DeprosperoDave Busters Entertainment
43
Clifford MarksNational CineMedia
56
Hui LiangNetSol Technologies
N/A
Margo ManningDave Busters Entertainment
52
Craig AbrahamsPlaytika Holding Corp
47
James PlunkettDave Busters Entertainment
65
Steve RooneySapiens International
N/A
Angelia PelhamDave Busters Entertainment
48
Sean GleasonDave Busters Entertainment
52
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California. Audentes Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people. Boundless Bio, Common (BOLD) is traded on NASDAQ Exchange in USA and employs 207 people.

Management Performance

Boundless Bio, Common Leadership Team

Elected by the shareholders, the Boundless Bio,'s board of directors comprises two types of representatives: Boundless Bio, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boundless. The board's role is to monitor Boundless Bio,'s management team and ensure that shareholders' interests are well served. Boundless Bio,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boundless Bio,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Soloway, CFO, Senior Vice President
Fulvio Mavilio, Senior Vice President - Translational Science
Andrew Chang, Director, Investor Relations
Eric Mosbrooker, Senior Vice President and Chief Commercial Officer
Jonathan Silverstein, Chairman of the Board
Thomas Woiwode, Independent Director
Mark Meltz, Senior Vice President General Counsel
Jennifer Jarrett, Director
Stephen Squinto, Independent Director
Edward Conner, Senior Vice President and Chief Medical Officer
Matthew Patterson, President CEO, Co-Founder, Director
Tom Woiwode, Board Director
David Nagler, Senior Vice President - Human Resources and Corporate Affairs
Louis Lange, Independent Director
Mary Newman, Senior Vice President - Regulatory Affairs
Scott Morrison, Independent Director
John Gray, Senior Vice President - Research and Development
Thomas Schuetz, Board Director
Suyash Prasad, Senior Vice President Chief Medical Officer
Mark Goldberg, Director
Sarah Spencer, Vice President Corporate Communications
Julie Smith, Director
Natalie Holles, COO, Senior Vice President
Kush Parmar, Board Director

Boundless Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boundless Bio, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Boundless Bio, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Boundless Bio,'s short interest history, or implied volatility extrapolated from Boundless Bio, options trading.

Pair Trading with Boundless Bio,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boundless Bio, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boundless Bio, will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to GameStop Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GameStop Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GameStop Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GameStop Corp to buy it.
The correlation of GameStop Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GameStop Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GameStop Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GameStop Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Boundless Stock

If you are still planning to invest in Boundless Bio, Common check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Boundless Bio,'s history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device